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Nodal peripheral T-cell lymphomas are a rare group of neoplasms derived from post-thymic
and activated T lymphocytes. A review of scientiﬁc articles listed in PubMed, Lilacs, and
the  Cochrane Library databases was performed using the term “peripheral T-cell lym-
phomas”. According to the World Health Organization classiﬁcation of hematopoietic tissue
tumors, this group of neoplasms consists of peripheral T-cell lymphoma not otherwise
speciﬁed (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell
lymphoma-anaplastic lymphoma kinase positive (ALCL-ALK+), and a provisional entity
called anaplastic large cell lymphoma-anaplastic lymphoma kinase negative (ALCL-ALK−).
Because the treatment and prognoses of these neoplasms involve different principles,
it  is essential to distinguish each one by its clinical, immunophenotypic, genetic, and
molecular features. Except for anaplastic large cell lymphoma-anaplastic lymphoma kinase
positive, which has no adverse international prognostic index, the prognosis of nodal periph-
eral  T-cell lymphomas is worse than that of aggressive B-cell lymphomas. Chemotherapy
based on anthracyclines provides poor outcomes because these neoplasms frequently have
multidrug-resistant phenotypes. Based on this, the current tendency is to use intensiﬁed
cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) regimens with the addi-
tion  of new drugs, and autologous hematopoietic stem cell transplantation. This paper
describes the clinical features and diagnostic methods, and proposes a therapeutic algo-
rithm for nodal peripheral T-cell lymphoma patients.© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Rua Dr. Ovídio Pires de Campos, 225, 1◦ anda
E-mail  address: tamicarvalho@hotmail.com (T.C.d.S. Cabral).
ttp://dx.doi.org/10.1016/j.bjhh.2015.03.017
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Introduction
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group
of malignancies of the immune system, encompassing
more  than 40 entities with speciﬁc clinical, morphologic,
immunophenotypic, and molecular characteristics. In the
Western World, NHLs originate from B lymphocytes in 85–90%
of cases and from lymphoid T cells and natural killer cells (NK)
in 10–15% of cases, while T-cell lymphomas represent a higher
proportion of NHL cases in Asian countries, accounting for up
to 25% of these neoplasms.1
T-cell malignancies derived from precursor or immature
T cells originate from leukemia-lymphoblastic T-cell lym-
phoma. Otherwise, the NHLs that originate from mature T
lymphocytes or NK cells are recognized as peripheral T-cell
lymphomas (PTCL). The latter represent 12–15% of all NHLs
and, according to the World Health Organization (WHO) Clas-
siﬁcation of Tumors, comprise 22 different entities categorized
according to clinical presentation as primary nodal, primary
extranodal, primary cutaneous, and disseminated or leukemic
forms as summarized in Table 1.1–3
This review discusses the main clinical and therapeutic
aspects of primary nodal PTCLs such as peripheral T-cell
lymphoma not otherwise speciﬁed (PTCL-NOS), angioim-
munoblastic T-cell lymphoma (AITL), anaplastic large-
cell lymphoma-anaplastic lymphoma kinase (ALK) positive
Table 1 – World Health Organization classiﬁcation of
peripheral natural killer (NK)/T-cell lymphomas.
Primary cutaneous lymphomas
Mycosis fungoides and Sézary syndrome
Primary cutaneous CD30+ T-cell lymphoproliferative disease
- Primary cutaneous anaplastic large-cell lymphoma (C-ALCL)
- Lymphomatoid papulosis (LYP)
Primary cutaneous peripheral T-cell lymphomas (PTCLs)
- Gama-delta T-cell lymphoma
- CD8+ aggressive epidermotropic cytotoxic
- CD4+ small-medium
Nodal peripheral T-cell lymphomas (PTCL)
Peripheral T-cell lymphoma not otherwise speciﬁed (PTCL-NOS)
Angioimmunoblastic T-cell lymphoma (AITL)
Anaplastic large-cell lymphoma (ALCL) anaplastic lymphoma kinase
(ALK) positive
Anaplastic large-cell lymphoma (ALCL) ALK negative (provisional)
Extranodal peripheral T-cell lymphomas
Extranodal NK-T-cell lymphoma, nasal type
Enteropathy-associated T-cell lymphoma (EATL)
Hepatosplenic T-cell lymphoma (HSTL)
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
Epstein–Barr virus (EBV)-positive T-cell lymphoproliferative childhood
disorders
- EBV-positive T-cell lymphoproliferative childhood disease
- Hydroa vacciniforme-like
Widespread or leukemic
T-cell prolymphocytic leukemia (T-PLL)
T-cell large granular lymphocytic leukemia (T-LGL)
Chronic lymphoproliferative disorders of NK cells (provisional)
Aggressive NK-cell leukemia
Adult T-cell leukemia/lymphoma 2 0 1 5;3  7(4):277–284
(ALCL-ALK+), and anaplastic large-cell lymphoma-ALK nega-
tive (ALCL-ALK−).
Methods
A systematic literature search using PubMed, Lilacs (Literatura
Latino-Americana e do Caribe em Ciências da Saúde), and the
Cochrane Library databases was conducted to identify sci-
entiﬁc papers related to the search term “peripheral T-cell
lymphomas”. Only papers focused on human subjects were
included.
Clinical  and  epidemiological  aspects
PTCL-NOS are represented by nodal or extranodal T-cell lym-
phomas not otherwise categorized as any speciﬁc entity in the
current WHO  classiﬁcation. These tumors represent 60–70%
of all PTCLs, and 5–7% of all NHLs. They occur more  com-
monly in adults with a median age of 60 years and have a
slight male predominance.4–6 Although lymph node involve-
ment predominates in the majority of cases, these lymphomas
often disseminate to the bone marrow, liver, spleen, and
other extranodal sites such as the skin and lung. They rarely
have a leukemic presentation.5,6 Patients often present with
unfavorable clinical characteristics including B symptoms,
elevated lactate dehydrogenase (LDH) levels, high tumor bur-
den, advanced disease (Stage III or IV), and poor performance
status.5,6
The AITL subtype is characterized by a speciﬁc clinical
syndrome and polymorphic inﬁltrate involving lymph nodes,
with proliferation of high endothelial venules in a tree-like
pattern and irregular proliferation of follicular dendritic cells
(FDC) with predominantly perivascular distribution. AITL rep-
resents the second most common subtype of PTCL (15–20% of
cases) with its prevalence only being exceeded by PTCL-NOS. It
occurs most commonly in elderly patients (aged 60–65 years),
with a slight male predominance.7
Typical cases of AITL show acute or subacute systemic
features that may mimic  drug reactions or systemic infec-
tions. Clinically, AITL presents as small and generalized
lymphadenopathy, hepatosplenomegaly, and constitutional
symptoms. Maculopapular rash occurs in 50% of cases and
paraneoplastic manifestations such as arthritis, vasculitis,
serous effusions, and neurological manifestations are not
uncommon. Laboratory features include eosinophilia, poly-
clonal hypergammaglobulinemia, elevated serum LDH and
erythrocyte sedimentation rate (ESR), as well as circulat-
ing autoantibodies (cryoagglutinins, cryoglobulins, immune
complexes, positive direct Coombs test) and paraneoplastic
phenomena of an immune nature (hemolytic anemia, leuko-
cytoclastic vasculitis, rheumatoid arthritis, and autoimmune
thyroid disease).1,4,7
ALCL is a PTCL characterized by large polymorphic lym-
phoid CD30+ cells with abundant cytoplasm and horseshoe-
or kidney-shaped nuclei. The three recognized subtypes are
+ −ALCL-ALK , ALCL-ALK , and primary cutaneous anaplastic
lymphoma.8 ALCL-ALK+ predominates in younger patients,
with a median age of 30 years, and represents 3–5% of NHLs
in adults and 30% of NHLs in children, with a male pre-
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Figure 1 – Morphologic aspects of Peripheral T-cell lymphoma not otherwise speciﬁed (PTCL-NOS). (A) Diffuse proliferation
of atypical medium sized lymphoid cells. Note some intermingled eosinophils [hematoxylin and eosin (H&E)-stained
section]. (B) Diffuse expression of CD3 by the neoplastic lymphoid cells. (C) These cells also express CD4. (D) CD7 antigen is
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wnly partially expressed by neoplastic T cells.
ominance. Extranodal involvement is frequent, and 50% of
ases are diagnosed at an advanced stage (III or IV) and in
atients with B symptoms. The most commonly involved sites
nclude the skin, subcutaneous tissue, bone, lung, and liver.
one marrow involvement occurs in 10–30% of cases, but the
eukemic phase is unusual and occurs more  frequently in
he small-cell morphological variant. It rarely presents with
astrointestinal and central nervous system involvement.
espite the advanced stage involving multiple extranodal
ites, most patients present with low-risk or low-intermediate
isk disease according to the International Prognostic Index
IPI), since performance status is frequently preserved and
ost patients are younger, with normal LDH levels at
iagnosis.4,9
ALCL-ALK− is morphologically indistinct from ALCL-ALK+,
ut does not show chromosomal translocations involving the
LK gene or expression of the ALK protein. The disease pre-
ominates in the elderly; extranodal involvement occurs in
p to half of cases and is usually diagnosed in patients with
dvanced stage disease who  have B symptoms and aggressive
isease. Recently, an unusual variant associated with pros-
hetic breast implants that has an indolent behavior has been
escribed.8–10
istopathological  and  molecular  diagnostic  criteria
n excisional tumor biopsy is essential for correct diagno-
is. Needle biopsy guided by imaging is not recommended.1 It
hould be highlighted that for the correct diagnosis and classi-
cation of PTCL, histopathological analysis by an experienced
ematopathologist using a large sample with a considerable
mount of tissue that allows visualization of the broad pattern
f lymph node inﬁltration is necessary, as well as applying a
ide immunohistochemical panel.In PTCL-NOS, the compromised lymph node shows para-
cortical or diffuse inﬁltration with loss of the normal lymph
node architectural pattern. Although large tumor cells pre-
dominate, a few cases exhibit small neoplastic cells. The
morphologic spectrum varies from monotonous to pleomor-
phic cells with an excess of mitotic cells (Figure 1). The
WHO  classiﬁcation recognizes histological variants such as
lymphoepitheliod lymphoma (Lennert lymphoma), follicular,
and T-like zone. Phenotypically, it exhibits aberrant anti-
gen expression characterized by a lack of T-cell markers
such as CD5 and CD7. Most cases express the CD4 antigen,
although some others may be CD8+, particularly the lym-
phoepitheliod variant. About 30% of PTCL-NOS express the
CD30 marker, but the phenotypic proﬁle and morphologic
aspect allow it to be distinguished from ALCL-ALK− since
the latter expresses epithelial membrane antigens (EMA) and
contains cytotoxic granules. Distinguishing it from classical
Hodgkin’s lymphoma (HL) can be achieved by observing the
expression of CD15, PAX-5, and Epstein–Barr virus (EBV). Also,
PTCL-NOS present with a high proliferative rate, with Ki67
higher than 70%, and strong and homogeneous expression of
CD3.1,4,11 Cases of PTCL CD30+/ALK− with no histologic simi-
larity to classic ALCL should be categorized as PTCL-NOS.1 A
monoclonal rearrangement of the T-cell receptor (TCR) gene is
usually seen in PTCL-NOS by polymerase chain reaction (PCR);
a cytogenetic abnormality with complex karyotype is the rule.
In the subtype with a follicular growth pattern, it is common to
observe the recurrent aberration t(5;9)(q33;q22) that produces
the oncogenic protein ITK-SYK.11
The morphological aspects of classical AITL include a dif-
fuse pattern of inﬁltration by polymorphic cells and variable
proportions of atypical neoplastic T-cells together with small
lymphocytes, histiocytes, immunoblasts, eosinophils, and
plasma cells with peri-lymph node inﬁltration into subcortical
sinuses. Likewise, there is prominent vascular proliferation
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Figure 2 – Morphologic aspects of angioimmunoblastic T-cell lymphoma. (A) Proliferation of small to medium sized
lymphoid cells with mild atypia surrounding prominent high endothelial venules. Occasional large cells are observed, as
well as some plasmocytes (H&E-stained section). (B) The majority of neoplastic lymphoid cells express membrane CD3. (C)
Neoplastic lymphoid cells also express CD10. (D) CD20 antibody highlights the large B immunoblasts. (E) Follicular dendritic
cell meshwork expansion surrounding high endothelial venules is evident with CD21 immunostain.
performance status. The mPIT distinguishes three differentwith a tree-like pattern of endothelial venules and irregular
proliferation of FDC. B immunoblasts are usually present in
the paracortical region and may mimic  HL (Figure 2). Neoplas-
tic cells express a pattern of follicular T helper cells such as
CD3+, CD4+, CD10+, BCL-6+, CXCL13+, PD1+, and ICOS+ cells.
Indeed, vascular expansion can be demonstrated by immuno-
histochemistry for CD31 and CD34. Irregular proliferation of
FDC can be deﬁned by CD21, CD23, and CD35 staining that
are often found with vessels. The B-cell-associated antigen
markers, such as CD20 and CD79a, may show immunoblasts
in the interfollicular areas. These cells are infected by EBV and
are Reed-Sternberg-like cells mimicking classical HL.7,11–14
Most of the AITL cases contain a monoclonal population of T
cells. The presence of B lymphocyte clones can be detected
in up to 30% of cases and the EBV genome is detected in
nearly 100%. Karyotypic aberrations occur in 70–80% of cases,
mainly trisomy of chromosome 3 and 5, and an additional X
chromosome.11,15
Although ALCL-ALK+ presents with a broad morphologi-
cal spectrum, all cases contain a variable proportion of cells
with eccentric nuclei (kidney-like or horseshoe-shaped) with
an eosinophilic perinuclear area corresponding to the Golgi,
and abundant cytoplasm; these cells are called ‘hallmark
cells’. The morphological ﬁndings of this disease vary from
small to very large malignant cells (Figure 3). In addition,
ﬁve distinct morphological patterns are recognized including
classical, lymphohistiocytic, small-cell, ‘Hodgkin-like’ variant,
and mixed pattern.9,11 The classical variants represent 60–70%
of all cases and their malignant cells are almost exclusively
large and sometimes Reed-Sternberg-like. When the lymph
node architecture is partially compromised, the cells grow
within sinusoids and may simulate metastatic tumors. The
cell phenotype exhibits diffuse positivity for CD30 and some-
times presents as a ‘perinuclear dot’ that corresponds to Golgi.
Expression of the CD2 antigen is common, but CD45RO, CD5,and CD7 are usually negative. Most patients present with a
CD4+/CD8− phenotype and show co-expression of cytotoxic
antigens such as granzyme B, TIA-1, perforin and the EMA
antigen.4,9,11 Most cases of ALCL-ALK+ have t(2;5)(p23;q35),
resulting in the hybrid product NPM1-ALK. In these cases, the
ALK protein can be found in both the cytoplasm and nucleus.
About 90% of these lymphomas have a clonal rearrangement
of the TCR gene. In addition to the classic t(2;5), a variant
chromosome translocation involving the ALK gene and other
genes located on chromosomes 1, 2, 3, 17, 19, 22, and X may
occur. The morphological and phenotypic aspects of ALCL-
ALK− cases are identical to those observed in ALCL-ALK+
cases.4,11,16
Prognostic  factors
Different studies have shown that the phenotype of T-cell lym-
phomas can be effectively stratiﬁed using the IPI.17,18 However,
a Prognostic Index for T-cell Lymphomas (PIT) was developed
in an attempt to produce more  accurate prognostic indicators.
This prognostic index identiﬁed four risk factors; age, serum
LDH, performance status, and histopathological involvement
of the bone marrow. Patients were stratiﬁed into four risk
groups with 0, 1, 2, or more  than 2 risk factors with overall
survival (OS) of 62%; 53%, 33%, and 18% for each risk group,
respectively.19
Another index is the modiﬁed Prognostic Index for T-cell
Lymphoma (mPIT), which incorporates a biological variable
(Ki67 expression) and clinical aspects such as age, LDH, andrisk groups: good risk prognosis, intermediate risk, and poor
risk.20 The International Peripheral T-cell Lymphoma Project
(IPTCLP) proposed another prognostic score that includes age,
performance status, and platelet count.18,21
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Figure 3 – Morphologic aspects of anaplastic large cell lymphoma-anaplastic lymphoma kinase (ALK) positive. (A) Diffuse
proliferation of large, highly atypical cells, with prominent pleomorphism (H&E-stained section). Some hallmark cells can
be observed; they present large multilobulated ‘horseshoe-like’ nuclei. Neoplastic cells show diffuse expression of (B) CD30;
(C) CD43; (D) epithelial membrane antigens and (E) ALK-1. In this case, ALK-1 positivity present exclusive cytoplasmic
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herapeutic  considerations
onventional multidrug regimens used for aggressive B
ell NHL such as CHOP are routinely considered for PTCL
reatment. However, the outcomes with anthracycline-based
egimens have been disappointing in patients with ALCL-
LK+ with low risk IPI.21–23 The worse outcome of PTCL is
he result of many  adverse factors such as high expression
f P-glycoprotein, which is associated with the anthracy-
line resistance phenotype (MDR phenotype).3 Usually, the
verall response rate is low and there is a high rate of
arly death during ﬁrst-line treatment. Relapses are com-
on  and often occur in the ﬁrst two years after treatment.
ecause of the lack of more  effective treatment for PTCL
hat is not ALK positive, the CHOP regimen remains the
ost commonly used ﬁrst-line therapy for these malignan-
ies. Several studies demonstrated complete response (CR)
ates of 50% and OS at 5 years of 30% with the CHOP
egimen.23
These disappointing results led to the investigation of new
herapeutic strategies such as intensiﬁed chemotherapy and
lternative protocols such as high-dose therapy followed by
escue with autologous hematopoietic stem cell transplanta-
ion (aHSCT). Although the results between different studies
ere discordant, an intensiﬁed CHOP regimen with the addi-
ion of etoposide has shown better progression-free survival
PFS), especially in under 60-year-old patients with favorable
isk factors.23–25
Although spontaneous remissions have been described,
ITL often presents with an aggressive clinical course.
ccasionally, asymptomatic patients may be observed or
reated with corticosteroids or immunomodulators and
ntiangiogenic drugs such as cyclosporine, thalidomide, and
evacizumab. In general, patients with AITL requiring ther-
py should be allocated to clinical studies. Of those, CHOP orﬂudarabine and cyclophosphamide (FC) regimens have been
used the most often.7,22,23
On the other hand, patients with ALCL-ALK+ without
adverse IPI risk factors have very chemosensitive disease
that responds with comparable or superior outcomes to
diffuse large B cell lymphoma (DLBCL) when treated with
anthracycline-based therapy. Several studies have demon-
strated overall response rate (ORR) of 90% with CHOP and
5-year OS of 70–80%. ALCL-ALK− and ALCL-ALK+ high risk
groups have an intermediate prognosis between ALCL-ALK+
without adverse risk factors and PTCL-NOS, with a 5-year OS
of 49% for ALCL-ALK− and 19% for PTCL-NOS. Currently, the
management of these patients is similar to those positive
for the variant ALK with low IPI, but because the outcome
is worse, the same approach used for PTCL-NOS is recom-
mended, with intensiﬁcation of CHOP by adding etoposide
or allocating patients to clinical trials or consolidation with
aHSCT.6,16,22,23
Usually, the therapeutic approach to PTCL does not involve
irradiation, which is reserved for bulky disease (tumor greater
than 10 cm)  or a residual mass after chemotherapy. However,
there is insufﬁcient evidence of clinical beneﬁts using this
approach. Many  groups have evaluated the role of aHSCT in
PTCL that is not ALK positive for ﬁrst CR or partial response
(PR). Although controversial, outside of the clinical trial set-
ting patients with AITL, ALCL-ALK− and PTCL-NOS should be
treated with CHOP-like therapy and consolidated with aHSCT
after the ﬁrst CR or PR.22,23,26–29
Patients with relapsed or refractory PTCL, acceptable per-
formance status, and no comorbidities should be treated with
platinum-based rescue chemotherapy followed by aHSCT.
There is still no consensus regarding allogeneic bone mar-
row transplantation in these patients, with mortality rates as
high as 30–50% when using myeloablative conditioning regi-
mens. This fact has promoted the use of reduced intensity
conditioning regimens in some cases.23,30,31
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Table 2 – Main characteristics of nodal peripheral T-cell lymphomas.
PTCL-NOS AITL ALCL-ALK+ ALCL-ALK-
Age
Gender
predominance
>60  years
Male
>60  years
Male
<40  years
Male
>60  years
Male
Clinical-laboratory
markers and
prognosis
Frequent extranodal
involvement;
Very aggressive
course
Nodal
predominance;
Splenomegaly;
Autoimmune
disorders;
Cutaneous rash;
Eosinophilia;
Hypergammaglobulinemia
Aggressive course;
Low and
low-intermediate
IPI;
Good prognosis,
particularly if low IPI
Aggressive course,
but better than
PTCL-NOS;
Intermediate
prognosis between
ALCL-ALK+ and
PTCL-NOS
Histopathology Monomorphic
inﬁltrate by small
and medium
lymphoid cells
Polymorphic
inﬁltrate;
Vascular
proliferation;
Follicular dendritic
cell proliferation;
Large immunoblasts
EBV+
Hallmark cells;
Mimic metastatic
carcinoma
Hallmark cells;
Mimic metastatic
carcinoma
Immunohistochemistry CD3+ (75%), CD4+,
CD7−, CD30+ or−
CD10+, BCL6+,
CXCL13+, PD1+,
ICOS+, EBV+
CD3+ (25%), CD4+,
CD30+ high, ALK1+
CD3+ (25%), CD4+,
CD30+ high, ALK–
Cytogenetics t(5;9) ITK-SYK +3, +5, +X t(2;5) NPM-ALK Non-speciﬁc
5-year overall
survival with
CHOP
19% 18% 70–80% 49%
Treatment option 6–8 CHO(E)P + aHSCT 6–8
(R)CHO(E)P + aHSCT
6–8  CHO(E)P 6–8 CHO(E)P + aHSCT
Potential new
therapeutic agents
Pralatrexate
Vorinostat
Bevacizumab
Lenalidomide
Crizotinib
Brentuximab
vedotin
Brentuximab
vedotin
PTCL-NOS: peripheral T-cell lymphoma not otherwise speciﬁed; AITL: angioimmunoblastic T-cell lymphoma; ALCL-ALK+: anaplastic large cell
lymphoma-anaplastic lymphoma kinase positive; ALCL-ALK−: anaplastic large cell lymphoma-anaplastic lymphoma kinase negative; IPI: Inter-
national Prognostic Index; EBV: Epstein–Barr virus; CHO(E)P: cyclophosphamide, doxorubicin, vincristine, prednisolone; aHSCT: autologous
hematopoietic stem cell transplantation.
For many  patients with PTCL, the available treatment
strategies are ineffective and new therapies should be
explored. Gemcitabine is a nucleoside analog that overcomes
the p-glycoprotein system. Bendamustine and antifolate
agents such as pralatrexate are being tested in these
lymphomas.32,33 Therapy with monoclonal antibodies such as
brentuximab vedotin (anti CD30), alemtuzumab (anti CD52),
and zanolimumab (anti CD4) have also been evaluated.
For the subgroup of PTCL patients whose tumors express
the CD30 antigen, particularly systemic ALCL and CD30+ PTCL-
NOS, brentuximab vedotin has emerged as an interesting
therapy. The antibody-drug conjugate combines a monoclonal
antibody directed against CD30 with a potent antimicrotubule
agent named monomethylauristatin E (MMAE). CD30 is an
ideal therapeutic target because of its strong and uniform
expression in anaplastic lymphoma. After binding to its tar-
get molecule, brentuximab vedotin is internalized and MMAE
is cleaved from the antibody molecule, exerting its action
through inhibition of microtubule formation. In a phase II
multicenter trial of brentuximab vedotin in relapsed and
refractory ALCL, the overall response rate was 86%, with a CR
rate of 53%. Signiﬁcant adverse events were peripheral neu-
ropathy, lung toxicity, neutropenia, and thrombocytopenia.34Another new interesting drug for the treatment of these
neoplasms is alisertib (MLN8237). This drug is a selective
inhibitor of Aurora A kinase (AAK), and shows preclinical
activity in PTCL cell lines and patient samples. Recently,
Friedberg et al. reported the interim results of a phase II
clinical trial of alisertib in patients with aggressive B and T-
cell NHL. ORR for the whole study population was 32%, but
when divided by subtype, patients with PTCL had an ORR of
57%.35
A better understanding of the pathophysiology of these
tumors is allowing the use of targeted therapies, such as
the ALK inhibitor crizotinib, modulators of epigenetic phe-
nomenon drugs able to restore the transcriptional status
of tumor suppressor genes (histone deacetylase inhibitors),
and immunomodulating agents that have greater antitumor
activity in AITL. Disease progression is associated with more
dysregulation of the immune system than tumor growth
phenomena.31,36–40
Table 2 shows a comparative analysis of the major epi-
demiological and clinical characteristics, pathological and
therapeutic approaches, prognosis, and new therapeutic
agents that can be employed in patients with each of the four
main entities discussed in this article.
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onclusion
rimary nodal peripheral T-cell lymphomas comprise a
eterogeneous group of neoplasms arising from the prolif-
ration of activated lymphoid T-cells. Clinical, morphologic,
mmunophenotypic, genetic, and molecular criteria are used
o classify these neoplasms, which are frequently difﬁcult
o diagnose. Correct identiﬁcation of each entity is criti-
al to establish appropriate therapeutic interventions, which
urrently still offer poor response rates. Intensiﬁcation of
reatment using new drugs or speciﬁc monoclonal antibod-
es, as well as HSCT, may change this reality in the near
uture. More  studies are necessary to deﬁne the best treatment
pproach for these entities.
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